FDA Panel Votes In Favor of Replimune’s Melanoma Treatment
An FDA expert committee has voted in favor of Replimune’s melanoma treatment, marking a significant shift for the company’s previously rejected drug.
Who reported it (5)
- FDA expert committee votes in favor of Replimune’s melanoma treatment STAT · 13h ago
- Replimune’s twice-rejected melanoma drug prevails in FDA adcomm Fierce Biotech · 13h ago
- US FDA advisers back Replimune skin cancer drug trial data Reuters · 13h ago
- Why Is REPL Stock Soaring 127% After Hours Today? finance.yahoo.com · 13h ago
- FDA Panel Votes In Favor of Replimune’s Melanoma Treatment WSJ · 13h ago
The story so far
Replimune shares surged 127% in after-hours trading following an FDA expert committee vote supporting the company's melanoma treatment. This endorsement follows two previous rejections for the drug, shifting the outlook for the biotech firm’s primary candidate. The advisory panel specifically backed the company's skin cancer drug trial data, providing a positive signal for the treatment's regulatory path.
Fierce Biotech, STAT, Reuters, WSJ, and Yahoo Finance report that the panel’s recommendation serves as a critical milestone for a therapy that had previously failed to clear regulatory hurdles. Investors reacted sharply to the news, as evidenced by the significant jump in REPL stock valuation after hours.
The FDA is not required to follow the advice of its expert committees, though it typically does so. Coverage does not yet specify a final timeline for an official regulatory decision regarding the drug's approval status.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. Updated 1h ago.
The obvious questions
What was the FDA committee's decision?
The FDA expert committee voted in favor of the clinical trial data for Replimune’s melanoma treatment.
How did the market react to this news?
REPL stock rose 127% in after-hours trading following the announcement.
Is the drug officially approved for use?
No, the advisory panel's vote is a recommendation. Coverage does not yet specify when the FDA will make its final determination.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
FDA Announces Recall on Berries Sold in 8 States for Potential E. Coli Contamination
The FDA and Publix have issued a recall for frozen berries across eight states following an E. coli outbreak linked to the products.
More cases reported in cyclospora outbreak not linked to lettuce: FDA data
Cyclospora infections are rising across the U.S., with recent data indicating new outbreak clusters that fall outside the traditional link to lettuce products.
Can you eat lettuce safely during the cyclospora outbreak? Advice from an infectious disease expert
Cyclospora outbreaks are fueling regional health concerns and economic strain in the restaurant industry as officials navigate complex data and public messaging.
Toward a test of medical AI superintelligence
A new medical AI framework sparks debate over FDA benchmarks and the path to superintelligence.
Cyclospora and salmonella outbreaks raise concerns about U.S. food safety
Rising cyclosporiasis cases push 11,000 infections into the spotlight as the U.S. food safety system faces fresh scrutiny
Hot Peptide Summer Is Almost Here
FDA panel OKs two peptides, rejects one, sparking a summer surge amid conflicting regulatory reports.